Ebolavirus in West Africa, and the use of experimental therapies or vaccines

BMC Biology

Volumn 12, Issue 1, 2014, Pages

  Hoenen, Thomas ^a   Feldmann, Heinz ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VIRUS;

VIRUS VACCINE;

AFRICA; EBOLAVIRUS; EPIDEMIC; EXPERIMENTAL THERAPY; HEMORRHAGIC FEVER, EBOLA; HUMAN; ISOLATION AND PURIFICATION; PROCEDURES;

AFRICA, WESTERN; DISEASE OUTBREAKS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; THERAPIES, INVESTIGATIONAL; VIRAL VACCINES;

EID: 84907261920     PISSN: None     EISSN: 17417007     Source Type: Journal    
DOI: 10.1186/s12915-014-0080-6     Document Type: Article

References (20)

1. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S: Emergence of Zaire Ebola Virus Disease in Guinea - Preliminary Report. N Engl J Med 2014, [Epub ahead of print].
2. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011, 377:849-862. 10.1016/S0140-6736(10)60667-8, 21084112.
3. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011, 204:S810-S816. 10.1093/infdis/jir299, 21987756.
4. Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med 2006, 12:206-215. 10.1016/j.molmed.2006.03.006, 16616875.
5. Grolla A, Jones S, Kobinger G, Sprecher A, Girard G, Yao M, Roth C, Artsob H, Feldmann H, Strong JE. Flexibility of mobile laboratory unit in support of patient management during the, Ebola-Zaire outbreak in the Democratic Republic of Congo. Zoonoses Public Health 2007, 2012:151-157.
6. Roddy P, Colebunders R, Jeffs B, Palma PP, Van Herp M, Borchert M. Filovirus hemorrhagic fever outbreak case management: a review of current and future treatment options. J Infect Dis 2011, 204:S791-S795. 10.1093/infdis/jir297, 21987752.
7. Wong G, Qiu X, Olinger GG, Kobinger GP. Post-exposure therapy of filovirus infections. Trends Microbiol 2014, 22:456-463. 10.1016/j.tim.2014.04.002, 24794572.
8. Hoenen T, Feldmann H. Reverse genetics systems as tools for the development of novel therapies against filoviruses. Expert Rev Anti Infect Ther 2014, 12:1253-1263. 10.1586/14787210.2014.948848, 25169588.
9. Qiu X, Wong G, Fernando L, Audet J, Bello A, Strong J, Alimonti JB, Kobinger GP: mAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 2013, 5:207ra143.
10. Pettitt J, Zeitlin L, Kim Do H, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly MH, Whaley KJ, Ingram MF, Zovanyi A, Heinrich M, Piper A, Zelko J, Olinger GG: Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 2013, 5:199ra113.
11. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP: Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014. doi:10.1038/nature13777.
12. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010, 375:1896-1905. 10.1016/S0140-6736(10)60357-1, 20511019.
13. Friedrich BM, Trefry JC, Biggins JE, Hensley LE, Honko AN, Smith DR, Olinger GG. Potential vaccines and post-exposure treatments for filovirus infections. Viruses 2012, 4:1619-1650. 10.3390/v4091619, 23170176.
14. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010, 29:304-313. 10.1016/j.vaccine.2010.10.037, 21034824.
15. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, Foulds KE, Cheng C, Wang L, Donaldson MM, Colloca S, Folgori A, Roederer M, Nabel GJ, Mascola J, Nicosia A, Cortese R, Koup RA, Sullivan NJ: Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014. doi:10.1038/nm.3702.
16. Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011, 204:S1075-S1081. 10.1093/infdis/jir349, 21987744.
17. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, Paragas J, Matthias L, Smith MA, Jones SM, Hensley LE, Feldmann H, Jahrling PB: Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008, 4:e1000225.
18. Mire CE, Miller AD, Carville A, Westmoreland SV, Geisbert JB, Mansfield KG, Feldmann H, Hensley LE, Geisbert TW: Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis 2012, 6:e1567.
19. Günther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, Nichol ST, Ströher U, Artsob H, Peters CJ, Ksiazek TG, Becker S, ter Meulen J, Olschläger S, Schmidt-Chanasit J, Sudeck H, Burchard GD, Schmiedel S. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011, 204:S785-S790. 10.1093/infdis/jir298, 21987751.
20. Hampton T. Largest-ever outbreak of ebola virus disease thrusts experimental therapies, vaccines into spotlight. JAMA 2014, 312:987-989. 10.1001/jama.2014.11170, 25162140.